Arbutus completed a discovery research and license agreement with X-Chem, Inc. and Proteros biostructures GmbH to focus on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (Mpro). In this collaboration, Arbutus will leverage X-Chem’s proprietary DNA-encoded screening library and chemistry capabilities, and Proteros’ structural biology expertise to accelerate the development of pan-coronavirus agents to treat COVID-19 and potential future coronavirus outbreaks.